Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;8(7):511.
doi: 10.21037/atm.2020.01.21.

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways

Cara A Rabik  1   2 , Jiawan Wang  1   2 , Christine A Pratilas  1   2
Affiliations
Editorial

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways

Cara A Rabik et al. Ann Transl Med. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.01.21). Dr. Pratilas reports grants from Kura Oncology, personal fees from Genentech/ Roche, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
    Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT. Melgar K, et al. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. doi: 10.1126/scitranslmed.aaw8828. Sci Transl Med. 2019. PMID: 31484791 Free PMC article.

References

    1. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86. 10.1016/j.ccr.2011.04.008 - DOI - PMC - PubMed
    1. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71. 10.1016/j.ccr.2010.10.031 - DOI - PMC - PubMed
    1. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. 10.1158/0008-5472.CAN-05-2925 - DOI - PMC - PubMed
    1. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009;106:4519-24. 10.1073/pnas.0900780106 - DOI - PMC - PubMed
    1. Lito P, Pratilas CA, Joseph EW, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-82. 10.1016/j.ccr.2012.10.009 - DOI - PMC - PubMed